Additional investigations of anti-CLPTM1L monoclonal antibodies in chemoresistant lung and pancreatic cancers suggest that CLPTM1L is a potential novel target for cancer therapeutics in various cancers.27 This evidence concerns the gene CLPTM1L and pancreatic neoplasm.